Zobrazeno 1 - 10
of 56
pro vyhledávání: '"J, Belón"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
P. Zamora, Jesus Gomez-Navarro, J. Feliu, Pilar García-Alfonso, Amalio Ordóñez, Enrique Espinosa, Pilar Garrido, J. Belón, M. González Barón, E. Blanco, C. García-Girón
Publikováno v:
Cancer. 78:211-216
BACKGROUND. Both the biochemical modulation and the continuous administration of 5-fluorouracil (5-FU) have achieved promising results in patients with gastric carcinoma. Conversely, several studies on gastric carcinoma have demonstrated that the com
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b83696d34e4804a725bd12d70782c4c8
https://doi.org/10.1002/(sici)1097-0142(19960715)78:2<211::aid-cncr4>3.0.co
https://doi.org/10.1002/(sici)1097-0142(19960715)78:2<211::aid-cncr4>3.0.co
Autor:
Antonio Antón, Colajori E, A. Villar-Grimalt, Candel Mt, García de Paredes Ml, Enrique Aranda, Massutí B, J M Jimeno, J. Belón
Publikováno v:
Tumori Journal. 80:124-127
Aims and background To evaluate a new anthracycline 4′-iodo-4′-deoxydoxorubicin (I-DOX) in patients with measurable advanced colorectal adenocarcinoma in a phase II study. Methods We investigated therapeutic activity and toxicities associated wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::42ae225a886f05d349cac77fdc78daa1
https://doi.org/10.1177/030089169408000207
https://doi.org/10.1177/030089169408000207
Autor:
M C, Camacho García, E, Redondo Martínez, A, Rey López, S I, Martínez de la Riva, J, Belón López-Tomasseti
Publikováno v:
Archivos espanoles de urologia. 51(1)
To describe a case of metanephric adenoma, a rare and little known tumor with no potential to malignancy. This tumor type can occasionally coexist with Wilms' tumor, with which it is histogenically related.A 54-year-old female patient was referred to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0101586b4f2c4703319d5f259315f68b
https://pubmed.ncbi.nlm.nih.gov/9557342
https://pubmed.ncbi.nlm.nih.gov/9557342
Autor:
M. González Barón, P. Zamora, Jaime Feliu, Elodie Blanco, A. Ruiz, J. Belón, J.M. Vincent, Carlos Jara, Pilar Garrido, C. García Girón, P. García Alfonso, Enrique Espinosa
Publikováno v:
Oncology. 54
The Oncopaz Cooperative Group designed a chemotherapy regimen to modulate UFT® (Tegafur and Uracil) with leucovorin. The regimen consisted of a high intravenous dose of leucovorin, followed by oral UFT® and oral leucovorin twice daily for 14 days.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a0760770b151630aaf83ea98e514d27
https://pubmed.ncbi.nlm.nih.gov/8978582
https://pubmed.ncbi.nlm.nih.gov/8978582
Autor:
J, Feliu, M, González Barón, C, García-Girón, E, Espinosa, P, García-Alfonso, J, Belón, E, Blanco, P, Garrido, A, Ordónez, J, Gómez-Navarro, P, Zamora
Publikováno v:
Cancer. 78(2)
Both the biochemical modulation and the continuous administration of 5-fluorouracil (5-FU) have achieved promising results in patients with gastric carcinoma. Conversely, several studies on gastric carcinoma have demonstrated that the combination of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5091524c5282f423201c7f21d4ba4cc4
https://pubmed.ncbi.nlm.nih.gov/8673994
https://pubmed.ncbi.nlm.nih.gov/8673994
Autor:
J. R. Delgado, J. Belón, P. Ballesteros, J. Valdivia, A. Irigoyen, V. Conde, R. Luque, A. Bezares, E. López, E. González-Flores
Publikováno v:
European Journal of Cancer Supplements. 1:S74-S75
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4c7251a7e16fa98bd4a117d84f4be918
https://doi.org/10.1016/s1359-6349(03)90274-6
https://doi.org/10.1016/s1359-6349(03)90274-6
Autor:
A, Villar-Grimalt, E, Aranda, B, Massutí, J, Belón, A, Antón, J M, Jimeno, M T, Candel, M L, García de Paredes, E, Colajori
Publikováno v:
Tumori. 80(2)
To evaluate a new anthracycline 4'-iodo-4'-deoxydoxorubicin (I-DOX) in patients with measurable advanced colorectal adenocarcinoma in a phase II study.We investigated therapeutic activity and toxicities associated with repeated courses of I-DOX 80 mg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1d1d8680507d445c5599ce6cd2c31c6b
https://pubmed.ncbi.nlm.nih.gov/8016902
https://pubmed.ncbi.nlm.nih.gov/8016902
Autor:
J. Belón, Jose Javier Sanchez, C. Fernández-Marto, Antonio Antón, A. Cervantes, Juan J. Cruz-Hernández, Alfredo Carrato, Carlos Camps, M. Garciá-Paredes, E. Aranda, Eduardo Díaz-Rubio, A. Tres
Publikováno v:
Cancer Treatment An Update ISBN: 9782817807676
Colorectal cancer has been traditionally considered a tumoral type resistant to chemotherapy. During the last decades, 5-Fluorouracil (FU) has been the standard single agent treatment of colon and rectum cancer with a low response rate (not higher th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b420906bca284de75fbbe79724570252
https://doi.org/10.1007/978-2-8178-0765-2_89
https://doi.org/10.1007/978-2-8178-0765-2_89
Publikováno v:
Journal of Clinical Oncology. 24:10678-10678
10678 Background: Previous studies suggest that combined treatment of chemotherapy + surgery + radiotherapy has a high survival rate in pts with locally advanced or inflammatory breast cancer. Primary objective was evaluate response rate. Secondary o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1ede743a4e9a8f76c16f1c155b05da51
https://doi.org/10.1200/jco.2006.24.18_suppl.10678
https://doi.org/10.1200/jco.2006.24.18_suppl.10678